Related Experiment Video
Updated: Jul 25, 2026

An In vitro Co-infection Model to Study Plasmodium falciparum-HIV-1 Interactions in Human Primary Monocyte-derived Immune Cells
Published on: August 15, 2012
Fanconi syndrome induced by tenofovir: A case report
Bouchra Lify1, G Dabo2, O Nascimento1
1Department of Nephrology, Hemodialysis and Transplantation, Ibn Rochd University Hospital, Casablanca, Morocco.
Abstract:
Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor discovered in the USA in 2001. It is currently the treatment of choice for patients co-infected with human immunodeficiency virus (HIV) and hepatitis B virus. Its antiretroviral efficacy and good tolerance are responsible for the higher frequency of prescriptions compared with other nucleoside analogs. However, it can induce acute renal toxicity causing impairment of the proximal tubular function of the kidney. This is highly dependent on factors such as associated co-prescription didanosine or a protease inhibitor "boosted" with ritonavir, preexisting renal insufficiency, low body weight, or presence of associated diabetes. In contrast, long-term renal toxicity remains highly debated. Some studies describe a decrease in estimated glomerular filtration rate during prolonged treatment with TDF. Others reported renal safety even during prolonged use. The differences between patients enrolled in the different studies, the measured parameters and their interpretation could explain these discrepancies. We describe a case of a patient infected with HIV, who presented with Fanconi syndrome with acute renal failure six months after starting antiretroviral treatment including tenofovir.
More Related Videos
Related Concept Videos
Retroviruses
Mechanisms of Retrovirus-induced Cancers
Nephrotic Syndrome I : Introduction
Cytomegalovirus Disease
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors

